As previous studies suggested that the inhibition of ALK and IGF1R pathways may potentiate chemotherapy and radiotherapy in lung cancer [59, 60], crizotinib might be an effective additional therapeutic agent in patients with aggressive ARMS tumours that overexpress ALK, MET and IGF1R proteins. This evidence concerns the gene MET and lung cancer.